Cargando…
Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane t...
Autores principales: | Mineo, J-F, Bordron, A, Quintin-Roué, I, Loisel, S, Ster, K L, Buhé, V, Lagarde, N, Berthou, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747695/ https://www.ncbi.nlm.nih.gov/pubmed/15328518 http://dx.doi.org/10.1038/sj.bjc.6602089 |
Ejemplares similares
-
Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001) -
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005) -
Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011) -
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007) -
3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
por: Ahmad, Aamir, et al.
Publicado: (2013)